BioVeris Completes Agreements with Children's Hospital & Research Center at Oakland

Article

GAITHERSBURG, Md. -- BioVeris Corporation announced today that it completed an option agreement with Children's Hospital & Research Center at Oakland (CHRCO) for exclusive patent rights to a unique vaccine candidate for Neisseria meningitidis serogroup B, which causes meningitis. Under the agreement with CHRCO, the company acquired an option for exclusive rights to commercialize products for possible use in the prevention, diagnosis and treatment of disease caused by Neisseria meningitidis serogroup B.

The company and CHRCO also entered into a separate Sponsored Research Agreement under which the company will sponsor up to $800,000 of research at CHRCO over a two-year period aimed at developing a vaccine candidate. If the company exercises its option for exclusive rights, it will be required to pay a license issue fee, as well as milestones fees for initiating and completing human clinical trials and securing regulatory approvals, and royalties on product sales.

Source: BioVeris Corporation

Related Videos
Picture at AORN’s International Surgical Conference & Expo 2024
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Infection Control Today Topic of the Month: Mental Health
Lucy S. Witt, MD, investigates hospital bed's role in C difficile transmission, emphasizing room interactions and infection prevention
Shelley Summerlin-Long, MPH, MSW, BSN, RN, senior quality improvement leader, infection prevention, UNC Medical Center, Chapel Hill, North Carolina
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
Christopher Reid, PhD  (Photo courtesy of Christopher Reid, PhD)
Paper with words antimicrobial resistance (AMR) and glasses.   (Adobe Stock 126570978 by Vitalii Vodolazskyi)
Association for the Health Care Environment (Logo used with permission)
Related Content